BioSig Technologies (BSGM) has provided an update.
BioSig Technologies, Inc. has appointed Ferdinand Groenewald as their interim chief financial officer and principal accounting officer, following the resignation of Frederick D. Hrkac. Groenewald, who brings extensive financial leadership experience from previous roles at Alaunos Therapeutics, Muscle Maker, Inc., and directorships at other Nasdaq-listed companies, will manage the company’s accounting and financial reporting under a consulting agreement. His compensation includes a monthly rate of $15,000 plus reimbursement for business expenses, with the option for either party to terminate the agreement with 30 days’ notice. The company publicized Groenewald’s new role in a recent press release.
For an in-depth examination of BSGM stock, go to TipRanks’ Stock Analysis page.
